Evidence map›Paper›PMID 39762207›Full record

ArticleBlood cancer journal2025

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.

Paul J Hengeveld, Joyce Schilperoord-Vermeulen, P Martijn Kolijn, Julie M N Dubois, Peter E Westerweel, Sabina Kersting, Arnon P Kater, Mark-David Levin, Anton W Langerak

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul J HengeveldDepartment of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-0070-138X
Joyce Schilperoord-VermeulenDepartment of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
P Martijn KolijnDepartment of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Julie M N DuboisDepartment of Hematology, Cancer Care Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Peter E WesterweelDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.ORCID http://orcid.org/0000-0002-0746-7039
Sabina KerstingDepartment of Hematology, Haga Hospital, the Hague, the Netherlands.
Arnon P KaterDepartment of Hematology, Cancer Care Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3190-1891
Mark-David Levin *Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.ORCID http://orcid.org/0000-0003-2139-3547
Anton W Langerak *Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands. a.langerak@erasmusmc.nl.ORCID http://orcid.org/0000-0002-2078-3220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39762207
PMCPMC11704144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.